Ovarian Hyperstimulation Syndrome – Symptoms and Treatment

Ovarian Hyperstimulation Syndrome - Symptoms and Treatment

Ovarian hyperstimulation syndrome (OHSS) is a medical condition that causes a woman to produce more estrogen than her body needs. The symptoms of this condition are varied, ranging from a mild, intermittent discomfort to a severe, life-threatening condition. It is a significant health burden that can lead to bed rest and even hospitalization. Severe cases require intensive medical care. In addition to the symptoms and possible medical complications, OHSS can be fatal for both the patient and the mother.

Ovarian Hyperstimulation Syndrome Symptoms

Ovarian hyperstimulation syndrome is one of the most serious complications of controlled ovarian hyperstimulation. It can occur if a woman undergoes fertility treatments that cause her ovaries to become enlarged or hyperstimulated. It is also a possible side effect of a genetic mutation in the follicle-stimulating hormone receptor. The ovaries become overly sensitive to this hormone and the serum shifts from the intravascular space to the third space, resulting in OHSS. It can lead to thromboembolic events, stroke, or loss of perfusion in an extremity.

The most common form of Ovarian Hyperstimulation Syndrome is mild, affecting up to one-third of women. Treatment for mild OHSS typically requires no treatment and is usually self-resolving in a week or two. In moderate cases, the patient may require bed rest, fluid administration, and frequent monitoring of electrolytes. A few women may have a pregnancy despite the symptoms of OHSS. If you’re wondering if you may be at risk for OHSS, you should consult a fertility doctor to get a proper diagnosis.

The most common symptoms of OHSS include nausea and weight gain due to fluid, and a decreased ability to urinate. However, if the symptoms are severe, you may experience shortness of breath and fluid collections in your abdomen. If the symptoms persist, your physician may prescribe medicines or suggest a surgery. Your doctor will discuss treatment options with you and monitor your condition closely. Ovarian hyperstimulation syndrome symptoms will vary from mild to severe, so it’s important to know the symptoms as early as possible.

OHSS is caused by an exaggerated response to the hormones in the body. It can occur spontaneously or as a complication of fertility treatments. However, OHSS is rarer in women who take oral fertility medications. Ovarian hyperstimulation syndrome may improve over time with treatment. Ovarian hyperstimulation syndrome symptoms are painful and may require hospitalization. So, you should seek treatment right away.

Check out this video Ovarian Hyperstimulation Syndrome

Predictive factors

The prevalence of allergic diseases was also elevated in patients with OHSS, with a prevalence of 56 % and 21 %, respectively, in the severe form. Although the effect of allergies on OHSS is unclear, the association between allergy and OHSS is plausible. A study on the influence of allergies on the severity of OHSS is warranted. In the meantime, there are several risk factors for OHSS that can predict its onset.

Early treatment is the key to preventing a serious case of OHSS. Preventing the disease in its early stages is critical to its prognosis. Treatment for OHSS may include intravenous fluids and medication for the symptoms and reduced ovarian activity. In some cases, a doctor may recommend manual drainage with a syringe to help alleviate symptoms. If symptoms of OHSS are persistent, the doctor may recommend freezing mature follicles to provide the ovaries with a rest.

Although COS has been found to be safe, a high response to controlled ovarian stimulation can result in OHSS. Ovarian hyperstimulation can cause serious complications and, in some cases, can be fatal. To prevent OHSS, a dopamine agonist can be used. In addition to this medication, another alternative is bromocriptine. In clinical trials, bromocriptine has shown promising results for OHSS prevention.

OHSS is an extremely painful condition in which ovaries are over-stimulated. High levels of the pregnancy hormone hCG lead to swelling and leakage of fluid. Women who undergo in vitro fertilisation with injectable medications are at increased risk for developing the condition. Genetic mutations in the hormone receptors are also known to increase the risk of developing the disorder. In severe cases, the symptoms include decreased urination and difficulty breathing. A doctor can conduct an ultrasound to look for any free fluid in the abdomen. Additionally, the ovaries may appear larger and swollen.

A woman’s response to COS is a key predictor of OHSS. Although high levels of estradiol do not cause OHSS, they can increase the expression of cystic fibrosis transmembrane conductance regulator, which increases vascular permeability and causes a massive shift of body fluids. High levels of estrogen can activate the renin-angiotensin system and secrete inflammatory mediators.

OHSS Treatment

The complication of gonadotropin stimulation, called ovarian hyperstimulation syndrome (OHSS), is an acute enlargement of the ovaries and the abrupt shift of intravascular fluid into the third space. While the etiopathogenesis of OHSS remains unclear, various preventive and therapeutic measures have been proposed. However, because this syndrome is a potentially life-threatening condition, treatment is largely empirical.

There are four different stages of OHSS. Mild OHSS may affect one in every three women. This type requires no treatment and will usually go away within a week. Moderate OHSS may require monitoring the patient’s fluid intake and output. Symptoms can range from mild abdominal discomfort to severe pain and can even lead to bleeding. In severe cases, the patient’s condition may lead to thrombosis, pleural effusion, and respiratory distress. Although the onset of severe OHSS varies widely, it should be suspected if there is a possible pregnancy.

The symptoms of OHSS include pain, nausea, and loss of appetite. It can occur during the luteal phase, early pregnancy, or even after conception, despite the fact that the symptoms are minor. In addition, OHSS may result in pregnancy failure. The symptoms are usually mild to moderate and may be accompanied by a loss of appetite or a bloated feeling. The cause of OHSS is unknown. The treatment of OHSS is currently a matter of clinical trial.

Individualizing the COS protocol is crucial for prevention. Through the use of hormonal and functional markers, an individual can tailor a COS protocol to her specific risk profile and desired outcomes. By analyzing each individual patient’s biomarkers, the risk of OHSS can be reduced or eliminated. The goal of the treatment is to improve ovarian function. While individualized COS is the best way to treat OHSS, there are a number of iCOS methods that may help prevent its occurrence.

In vitro oocyte maturation is another option. In vitro maturation allows the retrieved immature oocytes to be matured before fresh embryo transfer. A study of 56 patients with OHSS reported that 76 percent of oocytes matured in the laboratory prior to transfer. Clinical pregnancy rate was 46 percent. However, this method of treatment is still experimental and is currently only available in a few clinics.

OHSS Prevention

In recent years, the prevalence of assisted reproduction technology has skyrocketed, with robust evidence proving its safety and efficacy. One of the more serious risks is ovarian hyperstimulation syndrome, or OHSS. It is a rare iatrogenic complication that affects approximately one in every 450000 to 500000 cycles. The overall mortality rate is approximately one in every 500000 cases, depending on the severity of OHSS.

While no pharmacologic treatment fully prevents OHSS, adjuvant drug therapy is effective in improving the management of moderate to severe cases of OHSS. Treatment with aspirin, dopamine agonists, calcium infusions, and hCG is effective in reducing the risk of hyperstimulation, but not in preventing the syndrome. Other treatments include metformin.

While there are several standardized methods of reducing the risk of OHSS, the most effective preventative measure is to determine the risk factors and tailor the COS protocol to the patient’s specific biomarkers. Among these, iCOS (in vitro oocyte maturation) has been shown to reduce the rate of cycle cancellation and iatrogenic complications of COS and improve ART outcomes.

One possible cause of OHSS is the oversecretion of vascular endothelial growth factor (VEGF). hCG induces the ovarian secretion of vasoactive angiogenic factors. These substances increase vascular permeability and result in the loss of fluid into the third space, causing the syndrome. In the meantime, patients are at risk of recurrent ovarian hyperstimulation, which is a major cause of OHSS.

There is no cure for OHSS. Although there is no specific treatment for OHSS, some lifestyle changes can lower the risk of symptoms. Dopamine, a neurotransmitter found in the brain, is a neurotransmitter that improves mood, reduces stress, and protects the ovary from damage. Moreover, dopamine, which can cause hypertrophy, is found to be helpful in reducing symptoms of OHSS.

The Fertility Foundation is a fertility charity in the UK providing IVF Grants, support and education to couples, single women and same-sex couples.

Subscribe to our newsletter for more information on our charity and grants.